Biopelle, Inc. has launched Emepelle, the first and only clinically proven skincare line that safely and effectively helps address Estrogen Deficient Skin (EDS). Emepelle features MEP Technology, a patented, specifically designed ingredient that helps to non-hormonally restore the natural function of Estrogen Deficient Skin. The Emepelle product line consists of a serum and a night cream. 

“We are thrilled to announce the introduction of Emepelle for women with Estrogen Deficient Skin, a condition that affects millions of women in the US,” says Eric Fleming, President and COO of Biopelle, Inc. “At this time, there are no cosmeceuticals available that are clinically proven to safely and effectively help address estrogen deficiency of the skin. We are excited that there is finally a product that can empower women and help them manage the aging process of their skin more confidently.”

As women age, estrogen levels naturally decline. Although women may notice skin dryness or changes to the condition of their skin as they get older, they likely do not make the correlation with declining estrogen levels, Biopelle says. Low estrogen results in skin dryness, atrophy, wrinkling and thinning. In the first five years of menopause, low estrogen levels lead to a staggering 30% loss of the skin’s collagen and a subsequent 2.1% loss each year thereafter.